Article Text
Commentary
What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? ‘Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus’
Statistics from Altmetric.com
Footnotes
Contributors ML and HT drafted and finalised the paper together.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests ML and HLT have no competing interests directly related to this manuscript; ML received research funding from Gilead US company and Viiv company. ML gave consultancies to MSD and Viiv. HLT’s wife is a full-time employee of AbbVie and holds stocks in AbbVie, Abbott and Gilead. HLT served as a DSMB chair to a Novartis.
Provenance and peer review Commissioned; internally peer reviewed.